ST. PAUL, Minn. – In collaboration with The ALS Association, the American Academy of Neurology Foundation has announced the Clinician Scientist Development Award to support research in amyotrophic lateral sclerosis (ALS).
The Clinician Scientist Development Award will provide $75,000 per year for two years to an investigator who will focus on clinical research for ALS. At this time, only one drug (riluzole) is approved by the FDA for treatment of ALS. The ALS Association recently launched a major initiative to prioritize and bring promising compounds into clinical trials in a focused approach called Translational Research Advancing Therapy for ALS, or TREAT ALS.
Also known as Lou Gehrig's disease, ALS is characterized by the gradual degeneration and death of motor neurons. Many people with ALS usually die within three to five years from the onset of symptoms.
The AAN Foundation is seeking applications from neurologists who have completed residency training and are less than five years from completion of residency when funding would begin. Applicants must be licensed to practice medicine in the United States.
Award applications are due October 5, 2005. The recipient will be announced in January 2006.
The Clinician Scientist Development Award is funded by The ALS Association and the AAN Foundation. Funding for the inaugural award has been made possible by the generous donation from Hope for ALS in memory of its founder, Peter Rostworowski Clark.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
When there is no enemy within, the enemies outside cannot hurt you.
-- African proverb